Your Cart Item
Reports Within

Parameters

Reports Within:

Parameter Include:

Requisites
Measures

Number of red blood cells in the blood

Identifies

Red blood cell disorders

Measures: Number of red blood cells in the blood

Identifies: Red blood cell disorders

60
Mins

Homes

1M
Happy

Customers

4.9
Google

Rating

Certified

Labs

What is the maximum days the report can be obtained for the test

The report for the Myelodysplastic Syndrome (MDS) MRD Panel By Flowcytometry can be obtained within 7-10 business days.

What are the prerequisites for the test Myelodysplastic Syndrome (MDS) MRD Panel By Flowcytometry

Prerequisites for the test Myelodysplastic Syndrome (MDS) MRD Panel By Flowcytometry:

  • Patient must have a confirmed diagnosis of Myelodysplastic Syndrome (MDS)
  • Physician order for the test
  • Patient must not have received any blood transfusions within the past 3 months
  • Patient must not have received any chemotherapy within the past 2 weeks

What are the measure values for the test Myelodysplastic Syndrome (MDS) MRD Panel By Flowcytometry

  • CD34+ Myeloblasts: <5%
  • CD34+/CD117+ Hematogones: <1%
  • CD34+/CD117+ Myeloid precursors: <2%
  • CD34-/CD117+ Myeloid precursors: <2%
  • CD34+ Granulocytic precursors: <5%
  • CD34+ Monocytic precursors: <5%
  • CD34+ Erythroid precursors: <5%

What does this test Myelodysplastic Syndrome (MDS) MRD Panel By Flowcytometry identify?

  • Myelodysplastic Syndrome (MDS) MRD Panel By Flowcytometry identifies residual disease in patients with MDS.
  • It helps in monitoring the response to treatment and detecting minimal residual disease (MRD) after therapy.
  • The panel uses flow cytometry to analyze the expression of specific markers on abnormal cells in the bone marrow.
  • By identifying MRD, this test can help in determining the risk of disease progression and guiding further treatment decisions.

Why is this test Myelodysplastic Syndrome (MDS) MRD Panel By Flowcytometry taken?

  • Myelodysplastic Syndrome (MDS) MRD Panel By Flowcytometry test is taken to monitor minimal residual disease (MRD) in patients with MDS.
  • MRD refers to the small number of cancer cells that may remain in the body after treatment and can potentially cause a relapse.
  • The test helps in assessing the effectiveness of treatment and determining the risk of disease recurrence in MDS patients.
  • By analyzing the presence of MRD using flow cytometry, healthcare providers can make informed decisions regarding the patient's ongoing treatment plan.

No FAQs available.

Customer Google Rating